knowledge -WSS

knowledge

author：fashion 2025-09-27 09:45:32 - browse：92

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Grail is spending more than ever lobbying Congress

WSS

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Meta looks to target Twitter with a rival app called Threads

FDA scientists endorse Pfizer/BioNTech Covid

It costs an awful lot of money to give away a kidney

Did the public have the right to know Arthur Ashe had AIDS?

focus

knowledge

focus

Bright Health sells Medicare Advantage business to Molina

Physicians aren't 'burning out.' They're suffering from moral injury

As demand for Covid shots wanes, Moderna seeks its next success

Heart disease in astronauts blamed on cosmic radiation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Make 'food is medicine' a key part of White House nutrition meeting

Medicare details structure of new drug price negotiation program

The cancer stories no one wants to hear

Malaria cases in Florida and Texas: Here’s what you need to know

A controversial new treatment promises to make little people taller

knowledge

Inside the fall of star MIT scientist David Sabatini

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Study links childhood stress with decline in older age

Group behind ProMed defends move to subscription

Inside the fall of star MIT scientist David Sabatini

'Null' research findings aren't empty of meaning. Let's publish them

hotspot

focus

explore

Wikipedia